<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">J Inflamm Res</journal-id>
<journal-id journal-id-type="iso-abbrev">J Inflamm Res</journal-id>
<journal-id journal-id-type="publisher-id">JIR</journal-id>
<journal-id journal-id-type="pmc">jinres</journal-id>
<journal-title-group>
<journal-title>Journal of Inflammation Research</journal-title>
</journal-title-group>
<issn pub-type="epub">1178-7031</issn>
<publisher>
<publisher-name>Dove</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">32104044</article-id>
<article-id pub-id-type="pmc">7020934</article-id>
<article-id pub-id-type="publisher-id">240421</article-id>
<article-id pub-id-type="doi">10.2147/JIR.S240421</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Research</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>The Association Between Sortilin and Inflammation in Patients with Coronary Heart Disease</article-title>
<alt-title alt-title-type="running-authors">Han et al</alt-title>
<alt-title alt-title-type="running-title">Han et al</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Han</surname>
<given-names>Wenxiu</given-names>
</name>
<xref ref-type="aff" rid="AFF0001">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wei</surname>
<given-names>Zhijie</given-names>
</name>
<xref ref-type="aff" rid="AFF0002">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zhang</surname>
<given-names>Hailiang</given-names>
</name>
<xref ref-type="aff" rid="AFF0001">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Geng</surname>
<given-names>Chunmei</given-names>
</name>
<xref ref-type="aff" rid="AFF0001">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Dang</surname>
<given-names>Ruili</given-names>
</name>
<xref ref-type="aff" rid="AFF0001">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Yang</surname>
<given-names>Mengqi</given-names>
</name>
<xref ref-type="aff" rid="AFF0001">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zhang</surname>
<given-names>Jun</given-names>
</name>
<xref ref-type="aff" rid="AFF0003">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wang</surname>
<given-names>Changshui</given-names>
</name>
<xref ref-type="aff" rid="AFF0001">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Jiang</surname>
<given-names>Pei</given-names>
</name>
<xref ref-type="corresp" rid="AN0001"></xref>
<xref ref-type="aff" rid="AFF0001">1</xref>
</contrib>
<aff id="AFF0001"><label>1</label><institution>Department of Pharmacy, Jining First People’s Hospital, Jining Medical University</institution>, <addr-line>Jining</addr-line>
<addr-line>272011</addr-line>, <country>People’s Republic of China</country></aff>
<aff id="AFF0002"><label>2</label><institution>Department of Medical Administration, Jining First People’s Hospital, Jining Medical University</institution>, <addr-line>Jining</addr-line>
<addr-line>272011</addr-line>, <country>People’s Republic of China</country></aff>
<aff id="AFF0003"><label>3</label><institution>Department of Pharmacy, The First Affiliated Hospital of Zhengzhou University</institution>, <addr-line>Zhengzhou</addr-line>
<addr-line>450052</addr-line>, <country>People’s Republic of China</country></aff>
</contrib-group>
<author-notes>
<corresp id="AN0001">Correspondence: Pei Jiang; Ruili Dang <institution>Jining First People’s Hospital, Jining Medical University</institution>, <addr-line>Jining</addr-line>, <country>People’s Republic of China</country><phone>Tel/Fax +86 537 2106208</phone> Email jiangpeicsu@sina.com; rosydang@126.com</corresp>
</author-notes>
<pub-date pub-type="epub">
<day>10</day>
<month>2</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="collection">
<year>2020</year>
</pub-date>
<volume>13</volume>
<fpage>71</fpage>
<lpage>79</lpage>
<history>
<date date-type="received">
<day>28</day>
<month>11</month>
<year>2019</year>
</date>
<date date-type="accepted">
<day>21</day>
<month>1</month>
<year>2020</year>
</date>
</history>
<permissions>
<copyright-statement>© 2020 Han et al.</copyright-statement>
<copyright-year>2020</copyright-year>
<copyright-holder>Han et al.</copyright-holder>
<license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">
<license-p>This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at <ext-link ext-link-type="uri" xlink:href="https://www.dovepress.com/terms.php">https://www.dovepress.com/terms.php</ext-link> and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</ext-link>). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (<ext-link ext-link-type="uri" xlink:href="https://www.dovepress.com/terms.php">https://www.dovepress.com/terms.php</ext-link>).</license-p>
</license>
</permissions>
<abstract>
<sec id="S2001">
<title>Purpose</title>
<p>Inflammation is a key contributor to coronary heart disease (CHD). Sortilin is a sorting receptor and has been identified as a critical regulator of inflammatory response. Therefore, our study aimed to determine the link between circulating sortilin levels, proinflammatory cytokine levels, and the occurrence of CHD.</p>
</sec>
<sec id="S2002">
<title>Patients and Methods</title>
<p>Our study included 227 CHD patients and 101 matched healthy individuals. Circulating serum levels of sortilin and proinflammatory cytokines, including IL-1β, IL-6 and TNF-α, were assessed by a double-antibody sandwich enzyme-linked immunosorbent assay (DAS-ELISA). Linear regression and correlation analyses were used to estimate the associations between sortilin and proinflammatory cytokines. Moreover, six single-nucleotide polymorphisms (SNPs) spanning the sortilin and SORL1 genes were genotyped.</p>
</sec>
<sec id="S2003">
<title>Results</title>
<p>Elevated levels of sortilin (P=0.027) and proinflammatory cytokines IL-1β (P=0.013), IL-6 (P=0.000) and TNF-α (P=0.010) were observed in CHD patients compared to those in healthy controls. Furthermore, sortilin levels were significantly positively correlated with IL-1β (r=0.252, P=0.0001), IL-6 (r=0.250, P=0.0001) and TNF-α (r=0.180, P=0.0064) levels. Notably, sortilin polymorphisms were revealed to be associated with the occurrence of CHD and varying sortilin levels. Subjects with the rs599839 AA risk genotype for CHD had significantly higher sortilin levels than those with the GG and GA genotypes (P=0.000); the same tendency was also observed in the levels of the proinflammatory cytokines IL-1β (P=0.003) and TNF-α (P=0.000). Similarly, GG carriers of rs464218 with increased sortilin levels were found to be at increased risk for CHD (P=0.014). The levels of IL-1β (P=0.025) and IL-6 (P=0.015) were also increased in these patients.</p>
</sec>
<sec id="S2004">
<title>Conclusion</title>
<p>Our findings reveal that high sortilin levels may interact with inflammatory response to contribute to the occurrence of CHD. Considering that our clinical evidence suggests for the first time that sortilin involves in inflammatory response in CHD, the mechanistic role of sortilin in the progression of CHD deserves detailed investigation.</p>
</sec>
</abstract>
<kwd-group kwd-group-type="author">
<title>Keywords</title>
<kwd>sortilin</kwd>
<kwd>inflammation</kwd>
<kwd>SORL1</kwd>
<kwd>polymorphism</kwd>
<kwd>coronary heart disease</kwd>
</kwd-group>
<funding-group>
<funding-statement>The study was supported by the National Natural Science Foundation of China (81602846, 81703625) and Taishan Scholar Project of Shandong Province (tsqn201812159).</funding-statement>
</funding-group>
<counts>
<fig-count count="3"></fig-count>
<table-count count="3"></table-count>
<ref-count count="34"></ref-count>
<page-count count="9"></page-count>
</counts>
</article-meta>
</front>
<body>
<sec id="S0001" sec-type="intro">
<title>Introduction</title>
<p>Coronary heart disease (CHD) is the most common form of disease affecting the heart and is considered to be a major public health burden throughout the world. Atherosclerosis, as the pathological basis of CHD, has become a particular focus of attention worldwide. Atherosclerosis has long been considered a degenerative disease caused by the continuous accumulation of cholesterol in the arterial intima.<xref ref-type="bibr" rid="CIT0001">1</xref> However, more recent data have redefined atherosclerosis as a complex disorder of chronic inflammation.<xref ref-type="bibr" rid="CIT0002">2</xref>,<xref ref-type="bibr" rid="CIT0003">3</xref> Accumulating evidence has been published supporting the role of inflammation in the initiation and progression of atherosclerosis. Luc et al reported that active inflammatory processes may trigger plaque rupture and enhance the risk of a clinically significant atherothrombotic event, according to histopathological and immunochemical observations.<xref ref-type="bibr" rid="CIT0004">4</xref> Furthermore, data are emerging regarding the role of inflammation in typical dyslipidemia associated with elevated very-low-density lipoprotein (VLDL), low-density lipoprotein (LDL) and triglycerides as well as reduced high-density lipoprotein (HDL) levels.<xref ref-type="bibr" rid="CIT0005">5</xref> Importantly, proinflammatory cytokines such as interleukin-1β (IL-1β), interleukin-6 (IL-6) and tumor necrosis factor (TNF)-α are secreted in all phases of atherosclerotic lesion progression,<xref ref-type="bibr" rid="CIT0006">6</xref>,<xref ref-type="bibr" rid="CIT0007">7</xref> suggesting their potential role in the occurrence of CHD.</p>
<p>Sortilin and sortilin-related receptor 1 (SORL1, also known as SORLA) are members of the Vps10p domain receptor family that were discovered in the 1990s.<xref ref-type="bibr" rid="CIT0008">8</xref>,<xref ref-type="bibr" rid="CIT0009">9</xref> These two proteins have been extensively studied due to their functions as regulators of intracellular trafficking through their Vps10p domain. Due to playing an essential role in cell signaling by acting as sorting regulators or receptors/coreceptors, both sortilin and SORL1 are involved in many associated cellular disorders.<xref ref-type="bibr" rid="CIT0010">10</xref>,<xref ref-type="bibr" rid="CIT0011">11</xref> Recently, a few studies in sortilin knockout mice have reported that sortilin is involved in the regulation of cytokine secretion during immune responses through the control of IL-6 and Interferon-γ (IFN-γ) exocytosis.<xref ref-type="bibr" rid="CIT0012">12</xref> In addition to binding to IFN-γ and IL-6, sortilin has also been demonstrated to bind to other cytokines, such as Interferon-α (IFN-α), interleukin-17A, interleukin-10, and interleukin-12, in immune cells.<xref ref-type="bibr" rid="CIT0013">13</xref> Interestingly, evidence in HEK293 cells has shown that the endocytic receptor SORL1 may impact cellular uptake as well as IL-6 signaling.<xref ref-type="bibr" rid="CIT0014">14</xref> Conversely, knockdown of SORL1 reduces extracellular levels of the proinflammatory cytokine IL-6 in astrocyte cultures.<xref ref-type="bibr" rid="CIT0015">15</xref> Therefore, it is feasible to speculate that the serum sortilin level may interact with inflammatory response and be related to CHD susceptibility. Additionally, clinical studies identified sortilin as a risk factor for cardiovascular disease,<xref ref-type="bibr" rid="CIT0016">16</xref> and SORL1 is also considered to contribute to the development of atherogenesis.<xref ref-type="bibr" rid="CIT0017">17</xref> However, the mechanism is not entirely clear.</p>
<p>Although some basic research into the relationship among sortilin, inflammation and CHD has been undertaken, direct clinical evidence of sortilin level as a marker for CHD risk, as well as of the role of inflammation as a potential confounder of such an association, is lacking. To provide clinical evidence for our hypothesis, we determined the circulating serum levels of sortilin and proinflammatory cytokines, including IL-1β, IL-6 and TNF-α, in 227 CHD patients and 101 healthy controls. Furthermore, we genotyped the sortilin and SORL1 SNPs in these patients to further verify our findings.</p>
</sec>
<sec id="S0002">
<title>Materials and Methods</title>
<sec id="S0002-S2001">
<title>Participants</title>
<p>To investigate the involvement of sortilin in CHD patients, a total of 227 CHD patients and 101 matched healthy individuals were enrolled from the outpatient clinic of Jining First People’s Hospital in Shandong Province. This study was conducted in accordance with the Declaration of Helsinki and approved by the medical ethics committee of the Jining First People’s Hospital. The written informed consent was obtained from each participant prior to enrolment.</p>
<p>CHD was defined as significant coronary artery stenosis greater than 50% for at least one of the three major coronary arteries or major branches. The angiographic analyses were conducted and confirmed by at least two experienced cardiologists, who were blinded to the study’s objective and design. Participant enrolment was denied according to the presence of severe autoimmune disease, acute or chronic viral hepatitis, valvular heart disease, liver or renal failure, neoplastic disease, thyroid or adrenal gland disease and acute infectious disease. The drugs mainly used in CHD patients are as follows: 87% with lipid-lowering drug, 29% with angiotensin-converting enzyme inhibitor/angiotensin-receptor blocker, 23% with diuretic and 31% with calcium channel blocker, respectively. Additionally, the 101 matched healthy controls without any medications during recent 3 months were verified as non-CHD adults after being assessed through a series of examinations, such as medical history, clinical physical examination, radiographic chest examination, and electrocardiogram.</p>
</sec>
<sec id="S0002-S2002">
<title>Blood Chemistry Analysis</title>
<p>Peripheral venous blood samples were collected after overnight fasting. Serum samples were isolated and stored at −80 °C until analysis. Serum levels of very-low-density lipoprotein (VLDL), low-density lipoprotein (LDL) and triglycerides as well as high-density lipoprotein (HDL) were measured by commercially available kits supplied by ERBA Mannheim (Germany) and an ERBA autoanalyzer. Serum levels of sortilin, IL-1β, IL-6 and TNF-α were measured with a commercially available ELISA kit (Sigma-Aldrich, USA, for sortilin; R&amp;D Systems, USA, for IL-1β, IL-6 and TNF-α) according to the manufacturer’s protocol. Briefly, a 96-well plate precoated with an anti-human monoclonal antibody was provided by the manufacturer. The diluted standards, control specimens and unknown samples were pipetted into the appropriate wells. Subsequently, a second antibody labeled with horseradish peroxidase (HRP) was added to form an antibody-antigen-HRP labeled antibody complex. After incubation and washing steps to remove the unbound substances, a substrate solution was added and reacted with the complex above to produce measurable signals. After stopping the reaction with the stop reagent, the optical density values were measured at 450 nm using a microplate reader (BioRad). All of the serum samples were routinely analyzed in duplicate, and the results were averaged.</p>
</sec>
<sec id="S0002-S2003">
<title>Genetic Studies</title>
<p>A TIANamp Blood DNA kit (TIANGEN, China) was used to extract the genomic DNA from peripheral blood, and a NanoDrop-1000 (NanoDrop, USA) was used to detect the concentration and purity of sample DNA to ensure that the samples could be used for subsequent experiments. Six SNPs were selected in our study and primers for SNP typing were designed by the software Assay Design 3.1 (<xref ref-type="table" rid="T0001">Table 1</xref>). After polymerase chain reaction amplification, products were treated with shrimp alkaline phosphatase to dephosphorylate any unincorporated dNTPs. Then, an extension reaction was performed using iPLEX extension reagents (Agena Bioscience, USA) according to the manufacturer’s protocol. After resin purification, the PCR products were spotted onto SpectroCHIPs using a Nanodispenser RS1000. The detection of primer extension products was performed by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry, and the software Spectro-TYPER was used to automatically import and analyze the genotyping data with genotypes called based on the calculated mass of the extension products. Additionally, to validate the MassARRAY results, no less than 10% of DNA samples were randomly selected and genotyped again.<table-wrap id="T0001" orientation="portrait" position="float"><label>Table 1</label><caption><p>Primers of Target Gene Used in the PCR</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Gene</th><th colspan="1" rowspan="1">SNP</th><th colspan="1" rowspan="1">Ancestor Allele</th><th colspan="1" rowspan="1">Primer Sequence</th><th colspan="1" rowspan="1">Product Size (bp)</th></tr></thead><tbody><tr><td colspan="1" rowspan="2">Sortilin</td><td colspan="1" rowspan="2">rs646776</td><td colspan="1" rowspan="2">C</td><td colspan="1" rowspan="1">F: 5ʹ- ACGTTGGATGAGACACCACTGGCTGATAAG-3’</td><td colspan="1" rowspan="2">92</td></tr><tr><td colspan="1" rowspan="1">R: 5ʹ- ACGTTGGATGTGCTGATCCAGCTATTTGGG-3’</td></tr><tr><td colspan="1" rowspan="2">Sortilin</td><td colspan="1" rowspan="2">rs599839</td><td colspan="1" rowspan="2">G</td><td colspan="1" rowspan="1">F: 5ʹ- ACGTTGGATGAAGAGAAAGAAATAGGAGC-3’</td><td colspan="1" rowspan="2">119</td></tr><tr><td colspan="1" rowspan="1">R: 5ʹ- ACGTTGGATGAGCTTACTCTATGAGTCTTC-3’</td></tr><tr><td colspan="1" rowspan="2">Sortilin</td><td colspan="1" rowspan="2">rs464218</td><td colspan="1" rowspan="2">G</td><td colspan="1" rowspan="1">F: 5ʹ- ACGTTGGATGCAAGTACACTGTGAGAGCTG-3’</td><td colspan="1" rowspan="2">100</td></tr><tr><td colspan="1" rowspan="1">R: 5ʹ- ACGTTGGATGAACCCCACTTCTGTGTGTTC-3’</td></tr><tr><td colspan="1" rowspan="2">SORL1</td><td colspan="1" rowspan="2">rs2070045</td><td colspan="1" rowspan="2">T</td><td colspan="1" rowspan="1">F: 5ʹ- ACGTTGGATGTGTCAACTGAGTCCAGGAAG-3ʹ</td><td colspan="1" rowspan="2">147</td></tr><tr><td colspan="1" rowspan="1">R: 5ʹ- ACGTTGGATGGACGAGTACAACTGCAGTTC-3’</td></tr><tr><td colspan="1" rowspan="2">SORL1</td><td colspan="1" rowspan="2">rs2282649</td><td colspan="1" rowspan="2">C</td><td colspan="1" rowspan="1">F: 5ʹ- ACGTTGGATGGGTAAAGGGAACTTCAGACG-3’</td><td colspan="1" rowspan="2">158</td></tr><tr><td colspan="1" rowspan="1">R: 5ʹ- ACGTTGGATGCCCAGCATTTGCAGATTTAG-3’</td></tr><tr><td colspan="1" rowspan="2">SORL1</td><td colspan="1" rowspan="2">rs1010159</td><td colspan="1" rowspan="2">C</td><td colspan="1" rowspan="1">F: 5ʹ- ACGTTGGATGGGTTCACCACATAGCCATTC-3ʹ</td><td colspan="1" rowspan="2">150</td></tr><tr><td colspan="1" rowspan="1">R: 5ʹ- ACGTTGGATGGATACCCAAGGAAAGAACAG-3’</td></tr></tbody></table><table-wrap-foot><fn><p><bold>Abbreviation:</bold> SNP, single-nucleotide polymorphism.</p></fn></table-wrap-foot></table-wrap>
</p>
</sec>
<sec id="S0002-S2004">
<title>Statistical Analysis</title>
<p>The Hardy-Weinberg Equilibrium test was performed for every SNP in controls. Continuous variables were described as the mean ± standard deviation, and the differences were compared by Student’s <italic>t</italic>-test for normally distributed or nonparametric variables Mann–Whitney <italic>U</italic>-tests for skewed variables. Categorical variables were compared by the <italic>χ</italic><sup>2</sup> test. Correlations between sortilin and serum IL-1β, IL-6, and TNF-α were analyzed by Spearman correlation analysis. Significance was defined as a P value &lt;0.05 in all analyses. All analyses were conducted using the statistical software package SPSS 17.0 (SPSS Inc., Chicago, IL, USA).</p>
</sec>
</sec>
<sec id="S0003">
<title>Results</title>
<sec id="S0003-S2001">
<title>Basic Characteristics of the Subjects</title>
<p>Our study included 227 patients with CHD and 101 healthy control individuals. The demographic and clinical characteristics and blood lipids levels of the study participants are presented in <xref ref-type="table" rid="T0002">Table 2</xref>. As shown in <xref ref-type="table" rid="T0002">Table 2</xref>, there were no statistically significant differences in age, gender, BMI, smoking and drinking status between CHD patients and healthy control individuals (P&gt;0.05).<table-wrap id="T0002" orientation="portrait" position="float"><label>Table 2</label><caption><p>Demographic and Clinical Characteristics of the Study Participants</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Variables</th><th colspan="1" rowspan="1">CHD (n=227)</th><th colspan="1" rowspan="1">Controls (n=101)</th><th colspan="1" rowspan="1">P-value</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">Age (yrs)</td><td colspan="1" rowspan="1">51.27±6.914</td><td colspan="1" rowspan="1">49.93±8.046</td><td colspan="1" rowspan="1">0.125</td></tr><tr><td colspan="1" rowspan="1">Gender (M/F, n)</td><td colspan="1" rowspan="1">126/101</td><td colspan="1" rowspan="1">64/37</td><td colspan="1" rowspan="1">0.183</td></tr><tr><td colspan="1" rowspan="1">Smoking (n, %)</td><td colspan="1" rowspan="1">95(41.9)</td><td colspan="1" rowspan="1">36(35.6)</td><td colspan="1" rowspan="1">0.289</td></tr><tr><td colspan="1" rowspan="1">Drinking (n, %)</td><td colspan="1" rowspan="1">84(37.0)</td><td colspan="1" rowspan="1">32(31.7)</td><td colspan="1" rowspan="1">0.352</td></tr><tr><td colspan="1" rowspan="1">BMI (kg/m<sup>2</sup>)</td><td colspan="1" rowspan="1">23.82±2.878</td><td colspan="1" rowspan="1">23.43±2.290</td><td colspan="1" rowspan="1">0.191</td></tr><tr><td colspan="1" rowspan="1">VLDL (mmol/L)</td><td colspan="1" rowspan="1">0.82±0.290</td><td colspan="1" rowspan="1">0.69±0.303</td><td colspan="1" rowspan="1">0.001</td></tr><tr><td colspan="1" rowspan="1">LDL (mmol/L)</td><td colspan="1" rowspan="1">2.41±0.803</td><td colspan="1" rowspan="1">2.24±0.672</td><td colspan="1" rowspan="1">0.064</td></tr><tr><td colspan="1" rowspan="1">TG (mmol/L)</td><td colspan="1" rowspan="1">1.84±1.016</td><td colspan="1" rowspan="1">1.57±0.720</td><td colspan="1" rowspan="1">0.014</td></tr><tr><td colspan="1" rowspan="1">HDL (mmol/L)</td><td colspan="1" rowspan="1">1.19±0.265</td><td colspan="1" rowspan="1">1.27±0.249</td><td colspan="1" rowspan="1">0.011</td></tr></tbody></table><table-wrap-foot><fn><p><bold>Abbreviations:</bold> CHD, coronary heart disease; BMI, Body Mass Index; VLDL, very-low-density lipoprotein; LDL, low-density lipoprotein; TG, triglycerides; HDL, high-density lipoprotein.</p></fn></table-wrap-foot></table-wrap>
</p>
</sec>
<sec id="S0003-S2002">
<title>Correlation Between the Levels of Sortilin and the Three Proinflammatory Cytokines IL-1β, IL-6, TNF-α</title>
<p>Compared to healthy controls, CHD patients showed a significant increase in serum sortilin level (387.72 ± 151.0 ng/L vs 348.51 ± 139.9 ng/L, P = 0.027), as highlighted in <xref ref-type="fig" rid="F0001">Figure 1</xref>. Similarly, increased serum levels of IL-1β, IL-6 and TNF-α were also observed in CHD patients (IL-1β, 31.70 ± 12.789 ng/L vs 28.03 ± 11.185 ng/L, P=0.013; IL-6, 17.85 ± 10.705 ng/L vs 13.45 ± 9.605 ng/L, P = 0.000; TNF-α, 311.01 ± 167.5 ng/L vs 263.29 ± 119.6 ng/L, P = 0.010). Moreover, the serum sortilin level was significantly correlated with the IL-1β (r = 0.252, P = 0.0001), IL-6 (r = 0.250, P = 0.0001), and TNF-α (r = 0.180, P = 0.0064) levels (<xref ref-type="fig" rid="F0002">Figure 2</xref>).<fig fig-type="figure" id="F0001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Comparisons of serum sortilin (<bold>A</bold>), IL-1β (<bold>B</bold>), IL-6 (<bold>C</bold>) and TNF-α (<bold>D</bold>) levels among CHD patients and healthy individuals. Data are expressed as the mean ± SEM. *P &lt; 0.05, **P &lt; 0.01, ***P &lt; 0.001 compared between groups.</p></caption><graphic content-type="print-only" xlink:href="JIR-13-71-g0001"></graphic></fig><fig fig-type="figure" id="F0002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>The correlations between serum levels of sortilin and IL-1β (<bold>A</bold>), IL-6 (<bold>B</bold>), and TNF-α (<bold>C</bold>) in CHD patients. **P &lt; 0.01, ***P &lt; 0.001.</p></caption><graphic content-type="print-only" xlink:href="JIR-13-71-g0002"></graphic></fig></p>
</sec>
<sec id="S0003-S2003">
<title>Hardy-Weinberg Equilibrium Test</title>
<p>The genotype distribution of all SNPs in the control groups conformed to the Hardy-Weinberg equilibrium according to the <italic>χ</italic><sup>2</sup> test (rs646776: <italic>χ</italic><sup>2</sup> = 0.130, P = 0.718; rs599839: <italic>χ</italic><sup>2</sup> = 3.050, P = 0.081; rs464218: <italic>χ</italic><sup>2</sup> = 0.669, P = 0.413; rs2070045: <italic>χ</italic><sup>2</sup> = 0.532, P = 0.466; rs2282649: <italic>χ</italic><sup>2</sup> = 2.096, P = 0.148; and rs1010159: <italic>χ</italic><sup>2</sup> = 1.726, P = 0.189).</p>
</sec>
<sec id="S0003-S2004">
<title>Sortilin and SORL1 Polymorphisms</title>
<p>The genotypic frequencies of sortilin (rs646776, rs599839, and rs464218) and SORL1 (rs2070045, rs2282649, and rs1010159) polymorphisms are summarized in <xref ref-type="table" rid="T0003">Table 3</xref>. There were significant differences in the frequency of the sortilin polymorphisms (for rs599839, <italic>χ</italic><sup>2</sup> = 34.261, P = 0.000; for rs464218, <italic>χ</italic><sup>2</sup> = 8.008, P = 0.018) between CHD patients and healthy controls, while no significant difference in sortilin polymorphism (rs646776) was observed (P &gt; 0.05). For rs599839, when subdividing these samples into GG and GA + AA groups, an obvious difference between cases and controls was found (<italic>χ</italic><sup>2</sup> = 7.453, P = 0.006, OR = 8.378, 95% CI = 1.709–41.074). Similarly, for rs464218, a significant difference in the genotype frequency was also observed between CHD patients and healthy controls; the G allele (GG + GA) occurred significantly more frequently among the CHD patients than the controls (<italic>χ</italic><sup>2</sup> = 5.345, P = 0.021, OR = 0.573, 95% CI = 0.357–0.921). However, no significant differences in SORL1 polymorphisms were found between CHD patients and healthy controls (P &gt; 0.05).<table-wrap id="T0003" orientation="portrait" position="float"><label>Table 3</label><caption><p>Genotype Distributions of Sortilin and SORL1 Gene Polymorphisms in CHD and Control Group</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Gene</th><th colspan="1" rowspan="1">SNP</th><th colspan="1" rowspan="1">Genotype</th><th colspan="1" rowspan="1">CHD (n=227, %)</th><th colspan="1" rowspan="1">Controls (n=101, %)</th><th colspan="1" rowspan="1">OR (95% CI)</th><th colspan="1" rowspan="1"><italic>χ</italic><sup>2</sup></th><th colspan="1" rowspan="1">P-value</th></tr></thead><tbody><tr><td colspan="1" rowspan="4">Sortilin</td><td colspan="1" rowspan="4">rs646776 (C&gt;T)</td><td colspan="1" rowspan="1">CC</td><td colspan="1" rowspan="1">0(0)</td><td colspan="1" rowspan="1">0(0)</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">CT</td><td colspan="1" rowspan="1">25(11.0)</td><td colspan="1" rowspan="1">7(6.9)</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">TT</td><td colspan="1" rowspan="1">202(89.0)</td><td colspan="1" rowspan="1">94(93.1)</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">1.323</td><td colspan="1" rowspan="1">0.250</td></tr><tr><td colspan="1" rowspan="1">CC+CT</td><td colspan="1" rowspan="1">25(11.0)</td><td colspan="1" rowspan="1">7(6.9)</td><td colspan="1" rowspan="1">0.602(0.251–1.441)</td><td colspan="1" rowspan="1">1.147</td><td colspan="1" rowspan="1">0.284</td></tr><tr><td colspan="1" rowspan="4">Sortilin</td><td colspan="1" rowspan="4">rs599839 (G&gt;A)</td><td colspan="1" rowspan="1">GG</td><td colspan="1" rowspan="1">2(0.9)</td><td colspan="1" rowspan="1">7(6.9)</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">GA</td><td colspan="1" rowspan="1">15(6.6)</td><td colspan="1" rowspan="1">27(26.7)</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">AA</td><td colspan="1" rowspan="1">210(92.5)</td><td colspan="1" rowspan="1">67(66.3)</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">34.261</td><td colspan="1" rowspan="1"><bold>0.000</bold></td></tr><tr><td colspan="1" rowspan="1">GA+AA</td><td colspan="1" rowspan="1">225(99.1)</td><td colspan="1" rowspan="1">94(93.1)</td><td colspan="1" rowspan="1">8.378(1.709–41.074)</td><td colspan="1" rowspan="1">7.453</td><td colspan="1" rowspan="1"><bold>0.006</bold></td></tr><tr><td colspan="1" rowspan="4">Sortilin</td><td colspan="1" rowspan="4">rs464218 (G&gt;A)</td><td colspan="1" rowspan="1">GG</td><td colspan="1" rowspan="1">27(11.9)</td><td colspan="1" rowspan="1">4(4.0)</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">GA</td><td colspan="1" rowspan="1">101(44.5)</td><td colspan="1" rowspan="1">39(38.6)</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">AA</td><td colspan="1" rowspan="1">99(43.6)</td><td colspan="1" rowspan="1">58(57.4)</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">8.008</td><td colspan="1" rowspan="1"><bold>0.018</bold></td></tr><tr><td colspan="1" rowspan="1">GG+GA</td><td colspan="1" rowspan="1">128(56.4)</td><td colspan="1" rowspan="1">43(42.6)</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">5.345</td><td colspan="1" rowspan="1"><bold>0.021</bold></td></tr><tr><td colspan="1" rowspan="4">SORL1</td><td colspan="1" rowspan="4">rs2070045 (T&gt;G)</td><td colspan="1" rowspan="1">TT</td><td colspan="1" rowspan="1">46(20.3)</td><td colspan="1" rowspan="1">18(17.8)</td><td colspan="1" rowspan="1">0.573(0.357–0.921)</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">TG</td><td colspan="1" rowspan="1">106(46.7)</td><td colspan="1" rowspan="1">45(44.6)</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">GG</td><td colspan="1" rowspan="1">75(33.0)</td><td colspan="1" rowspan="1">38(37.6)</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">0.710</td><td colspan="1" rowspan="1">0.701</td></tr><tr><td colspan="1" rowspan="1">TT+TG</td><td colspan="1" rowspan="1">152(67.0)</td><td colspan="1" rowspan="1">63(62.4)</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">0.650</td><td colspan="1" rowspan="1">0.420</td></tr><tr><td colspan="1" rowspan="4">SORL1</td><td colspan="1" rowspan="4">rs2282649 (C&gt;T)</td><td colspan="1" rowspan="1">CC</td><td colspan="1" rowspan="1">50(22.0)</td><td colspan="1" rowspan="1">21(20.8)</td><td colspan="1" rowspan="1">0.818(0.502–1.333)</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">CT</td><td colspan="1" rowspan="1">104(45.8)</td><td colspan="1" rowspan="1">42(41.6)</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">TT</td><td colspan="1" rowspan="1">73(32.2)</td><td colspan="1" rowspan="1">38(37.6)</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">0.947</td><td colspan="1" rowspan="1">0.623</td></tr><tr><td colspan="1" rowspan="1">CC+CT</td><td colspan="1" rowspan="1">154(67.8)</td><td colspan="1" rowspan="1">63(62.4)</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">0.932</td><td colspan="1" rowspan="1">0.334</td></tr><tr><td colspan="1" rowspan="4">SORL1</td><td colspan="1" rowspan="4">rs1010159 (C&gt;T)</td><td colspan="1" rowspan="1">CC</td><td colspan="1" rowspan="1">76(33.5)</td><td colspan="1" rowspan="1">40(39.6)</td><td colspan="1" rowspan="1">0.786(0.482–1.282)</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">CT</td><td colspan="1" rowspan="1">101(44.5)</td><td colspan="1" rowspan="1">42(41.6)</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">TT</td><td colspan="1" rowspan="1">50(22.0)</td><td colspan="1" rowspan="1">19(18.8)</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">1.220</td><td colspan="1" rowspan="1">0.543</td></tr><tr><td colspan="1" rowspan="1">CT+TT</td><td colspan="1" rowspan="1">151(66.5)</td><td colspan="1" rowspan="1">61(60.4)</td><td colspan="1" rowspan="1">1.303(0.802–2.116)</td><td colspan="1" rowspan="1">1.147</td><td colspan="1" rowspan="1">0.284</td></tr></tbody></table><table-wrap-foot><fn><p><bold>Note:</bold> P-value &lt; 0.05 has been bolded.</p><p><bold>Abbreviations:</bold> CHD, coronary heart disease; CI, confidence interval; OR, odds ratio; SNP, single-nucleotide polymorphism.</p></fn></table-wrap-foot></table-wrap>
</p>
</sec>
<sec id="S0003-S2005">
<title>Association of Sortilin Polymorphisms with Serum Levels of Sortilin, IL-1β, IL-6 and TNF-α</title>
<p>As shown in <xref ref-type="fig" rid="F0003">Figure 3</xref>, for rs599839, GG and GA carriers were combined because of the small number of GG carriers. The sortilin serum levels in the carriers of the risk genotype for CHD, AA, were significantly higher than those of the GG and GA carriers (391.25 ± 128.249 ng/L vs 314.70 ± 64.652 ng/L, P=0.000, <xref ref-type="fig" rid="F0003">Figure 3A</xref>), and the same trend was also observed for IL-1β (25.62 ± 7.311 ng/L vs 32.19 ± 13.020 ng/L, P = 0.003, <xref ref-type="fig" rid="F0003">Figure 3B</xref>) and TNF-α levels (233.80 ± 55.940 ng/L vs 317.60 ± 172.039 ng/L, P = 0.000, <xref ref-type="fig" rid="F0003">Figure 3D</xref>). Similarly, a significant difference was observed in the serum sortilin level among three different rs464218 genotypes (P = 0.039), and the sortilin level in CHD patients with the risk genotype, GG, was significantly higher than that in patients with the AA genotype (433.02 ± 118.100 ng/L vs 366.31 ± 116.403 ng/L, P = 0.014, <xref ref-type="fig" rid="F0003">Figure 3E</xref>); the same trend was evident in the IL-1β (38.80 ± 18.223 ng/L vs 28.58 ± 8.802 ng/L, P = 0.025, <xref ref-type="fig" rid="F0003">Figure 3F</xref>) and IL-6 levels (26.16 ± 17.343 ng/L vs 15.77 ± 7.149 ng/L, P = 0.015, <xref ref-type="fig" rid="F0003">Figure 3G</xref>).<fig fig-type="figure" id="F0003" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Association of sortilin polymorphisms with serum levels of sortilin, IL-1β, IL-6 and TNF-α in CHD patients. (<bold>A</bold>–<bold>D</bold>) rs599839 (<bold>E</bold>–<bold>H</bold>) rs464218. *P &lt; 0.05, **P &lt; 0.01, ***P &lt; 0.001 compared between groups.</p></caption><graphic content-type="print-only" xlink:href="JIR-13-71-g0003"></graphic></fig></p>
</sec>
</sec>
<sec id="S0004">
<title>Discussion</title>
<p>Sortilin, a 95-kDa protein expressed in a wide range of tissues including the brain, spinal cord, heart, and skeletal muscle, participates in intracellular protein sorting between the trans-Golgi network and endosomes.<xref ref-type="bibr" rid="CIT0008">8</xref> This sorting receptor is expressed at the cell surface and acts as an endocytotic receptor for various extracellular ligands in lipid metabolism<xref ref-type="bibr" rid="CIT0018">18</xref>,<xref ref-type="bibr" rid="CIT0019">19</xref> and the neuronal system,<xref ref-type="bibr" rid="CIT0020">20</xref>,<xref ref-type="bibr" rid="CIT0021">21</xref> where it facilitates the recycling or lysosomal degradation of internalized ligands. Preclinical in vivo evidence suggests that sortilin plays a significant role in the pathogenesis of vascular and metabolic disorders, including atherosclerosis, through contributions to arterial wall inflammation<xref ref-type="bibr" rid="CIT0010">10</xref>,<xref ref-type="bibr" rid="CIT0012">12</xref> and calcification<xref ref-type="bibr" rid="CIT0022">22</xref> and dysregulation of lipoprotein metabolism.<xref ref-type="bibr" rid="CIT0023">23</xref>,<xref ref-type="bibr" rid="CIT0024">24</xref> We found that patients with CHD presented a significantly higher sortilin level than healthy controls. Consistent with our results, recent clinical findings demonstrated increased sortilin levels in CHD patients with comorbid diabetes mellitus,<xref ref-type="bibr" rid="CIT0025">25</xref> suggesting its potential role as a biomarker for CHD. Although preclinical and clinical studies have demonstrated the vital role of sortilin in cardiovascular disease, the mechanism by which sortilin mediates CHD is unclear.</p>
<p>Inflammation is an immune response to harmful stimuli. Inflammation mechanisms are controlled by proinflammatory cytokines including IL-1β, IL-6 and TNF-α, inducing complex intracellular pathway signaling. Accumulating data are emerging regarding the role of IL-1β and TNF-α in atherosclerosis due to the recruitment of inflammatory cells to the site of injury or the promotion of adverse vascular smooth muscle cell remodeling.<xref ref-type="bibr" rid="CIT0026">26</xref>,<xref ref-type="bibr" rid="CIT0027">27</xref> Indeed, increased circulating levels of the inflammatory cytokines TNF-α and IL-6 are observed in CHD patients.<xref ref-type="bibr" rid="CIT0028">28</xref>,<xref ref-type="bibr" rid="CIT0029">29</xref> In our study, an elevated sortilin level was found in CHD patients. Considering that sortilin has been demonstrated to bind inflammatory cytokines, such as IFN-γ, IL-6, IFN-α, and IL-10 in immune cells, and is involved in the stimulation of IL-1β, C-C motif chemokine ligand 2, and TNF gene expression in murine microglia,<xref ref-type="bibr" rid="CIT0030">30</xref> it is reasonable to hypothesize that the sortilin level may interact with inflammatory response and be associated with the susceptibility to CHD. To test our hypothesis, serum levels of sortilin and three proinflammatory cytokines were determined by ELISA. Significant increases in serum sortilin, IL-1β, IL-6 and TNF-α levels were observed in CHD patients. To further estimate the associations between sortilin and proinflammatory cytokines, linear regression and correlation analyses were used. The analysis showed that the sortilin level was strongly positively correlated with the levels of three proinflammatory cytokines, IL-1β, IL-6 and TNF-α, supporting our hypothesis on the role of sortilin-mediated inflammation in the development of CHD. In support of our findings, recent studies on a C57BL/6 mouse model of atherosclerosis demonstrated that loss of sortilin impairs the secretion of IL-6 and IFN-γ cytokines in macrophages and Th1 cells,<xref ref-type="bibr" rid="CIT0012">12</xref> reducing the inflammatory component of vascular lesions and ultimately resulting in decreased atherosclerosis. Our study provides the first clinical evidence of the involvement of sortilin in inflammatory response during the pathogenesis of CHD.</p>
<p>To further validate the key role of sortilin in CHD, six sortilin and SORL1 SNPs were selected and genotyped using the Agena Biosciences MassArray platform. We discovered an association between the sortilin polymorphisms rs599839 and rs464218 and susceptibility to CHD. However, significant differences in SORL1 gene polymorphisms were not found between CHD patients and healthy controls. Notably, the genetic polymorphism analysis confirmed that the incidence of CHD was related to serum sortilin levels. Specifically, for rs599839, the serum sortilin level in the carriers of the CHD risk genotype, AA, was significantly higher than that in the GG and GA carriers. Likewise, for rs464218, individuals with the GG genotype with increased sortilin levels were found to be at increased risk of CHD. Interestingly, for rs599839, we discovered the same tendency that the CHD patients with the AA genotype had higher IL-1β and TNF-α levels than patients with the GG and GA genotype; for rs464218, increased IL-1β and IL-6 levels were also observed in patients with the risk genotype GG. No significant differences were observed in IL-6 (for rs599839) and TNF-α (for rs464218) levels between the two groups, respectively. These negative results can be explained by regional racial bias, a relatively small sample size. Additionally, the serum levels of inflammatory cytokines may be affected by the drugs. In summary, sortilin polymorphisms are associated with increased serum sortilin and proinflammatory cytokines levels and an increased risk of CHD, suggesting that the SNP effects are mediated by increased sortilin levels and subsequently elevated proinflammatory cytokine levels. It is noteworthy that genome-wide association studies have demonstrated an association between sortilin and CHD,<xref ref-type="bibr" rid="CIT0031">31</xref>,<xref ref-type="bibr" rid="CIT0032">32</xref> but this association is due to its regulation of hepatic lipoprotein metabolism.<xref ref-type="bibr" rid="CIT0023">23</xref>,<xref ref-type="bibr" rid="CIT0033">33</xref> Furthermore, other studies also demonstrated that the genetic variant rs599839 is prominently associated with CHD risk and that the genetic variants of chromosome 1p13 increase the risk of CHD via increased total cholesterol and LDL-cholesterol levels and decreased HDL-cholesterol levels.<xref ref-type="bibr" rid="CIT0034">34</xref> Overall, our findings emphasize that the key role of sortilin in CHD may be affected by intricate mechanisms, including inflammation and lipid metabolism.</p>
</sec>
<sec id="S0005">
<title>Conclusion</title>
<p>Our study demonstrates that CHD patients have higher sortilin and proinflammatory cytokine levels than healthy controls. Additionally, the sortilin level is positively related to proinflammatory cytokine levels, suggesting that sortilin may interact with inflammatory response to contribute to the occurrence of CHD. Moreover, individuals with a CHD risk allele presented increased sortilin levels, further validating the vital role of sortilin in CHD. Collectively, our study for the first time provided clinical evidence that sortilin involves in inflammatory response in CHD. CHD is a multifactorial disease, and the sortilin serum levels indeed do not rule out the effect of the drugs used in patients with non-first-episode CHD. Therefore, replication with large clinical samples, more mechanistic approach and more detail animal and cell experiments are needed to explore the mechanistic pathway between sortilin and inflammation in our study.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgments</title>
<p>We would like to thank all participants for their contributions and all organizations providing technical and financial support for this study.</p>
</ack>
<sec id="S0006">
<title>Ethics Approval and Informed Consent</title>
<p>Our study was approved by the medical ethics committee of the Jining First People’s Hospital, and the written informed consent was obtained from each participant prior to enrolment.</p>
</sec>
<sec id="S0007">
<title>Consent for Publication</title>
<p>Not applicable.</p>
</sec>
<sec id="S0008">
<title>Data Sharing Statement</title>
<p>The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.</p>
</sec>
<sec id="S0009">
<title>Author Contributions</title>
<p>Wenxiu Han and Zhijie Wei are co-first authors. PJ was responsible for the conception and design of the study. HLZ, CMG, CSW and MQY collected the samples and analyzed the basic clinical data; RLD, HLZ, CMG and MQY performed the genotyping; WXH and ZJW were involved the statistical analysis and drafting of the paper; RLD, JZ, ZJW and PJ interpreted the results and undertook critical revision of the manuscript. All authors contributed to data analysis, drafting and revising the article, gave final approval of the version to be published, and agree to be accountable for all aspects of the work.</p>
</sec>
<sec id="S0010" sec-type="COI-statement">
<title>Disclosure</title>
<p>The authors declare no conflicts of interest in this work.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="CIT0001">
<label>1.</label>
<mixed-citation publication-type="journal"><string-name><surname>Dai</surname>
<given-names>W</given-names></string-name>, <string-name><surname>Li</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Lv</surname>
<given-names>YN</given-names></string-name>, et al. <article-title>The roles of a novel anti-inflammatory factor, milk fat globule-epidermal growth factor 8, in patients with coronary atherosclerotic heart disease</article-title>. <source/><italic toggle="yes">Atherosclerosis</italic>. <year>2014</year>;<volume>233</volume>(<issue>2</issue>):<fpage>661</fpage>–<lpage>665</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2014.01.013</pub-id><pub-id pub-id-type="pmid">24561551</pub-id></mixed-citation>
</ref>
<ref id="CIT0002">
<label>2.</label>
<mixed-citation publication-type="journal"><string-name><surname>Patel</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Celermajer</surname>
<given-names>DS</given-names></string-name>, <string-name><surname>Bao</surname>
<given-names>S</given-names></string-name>. <article-title>Atherosclerosis-underlying inflammatory mechanisms and clinical implications</article-title>. <source/><italic toggle="yes">Int J Biochem Cell Biol</italic>. <year>2008</year>;<volume>40</volume>(<issue>4</issue>):<fpage>576</fpage>–<lpage>580</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.biocel.2007.11.017</pub-id><pub-id pub-id-type="pmid">18203647</pub-id></mixed-citation>
</ref>
<ref id="CIT0003">
<label>3.</label>
<mixed-citation publication-type="journal"><string-name><surname>Libby</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Theroux</surname>
<given-names>P</given-names></string-name>. <article-title>Pathophysiology of coronary artery disease</article-title>. <source/><italic toggle="yes">Circulation</italic>. <year>2005</year>;<volume>111</volume>(<issue>25</issue>):<fpage>3481</fpage>–<lpage>3488</lpage>. doi:<pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.105.537878</pub-id><pub-id pub-id-type="pmid">15983262</pub-id></mixed-citation>
</ref>
<ref id="CIT0004">
<label>4.</label>
<mixed-citation publication-type="journal"><string-name><surname>Luc</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Bard</surname>
<given-names>JM</given-names></string-name>, <string-name><surname>Juhan-Vague</surname>
<given-names>I</given-names></string-name>, et al. <article-title>C-reactive protein, interleukin-6, and fibrinogen as predictors of coronary heart disease: the PRIME Study</article-title>. <source/><italic toggle="yes">Arterioscler Thromb Vasc Biol</italic>. <year>2003</year>;<volume>23</volume>(<issue>7</issue>):<fpage>1255</fpage>–<lpage>1261</lpage>. doi:<pub-id pub-id-type="doi">10.1161/01.ATV.0000079512.66448.1D</pub-id><pub-id pub-id-type="pmid">12775578</pub-id></mixed-citation>
</ref>
<ref id="CIT0005">
<label>5.</label>
<mixed-citation publication-type="journal"><string-name><surname>Escarcega</surname>
<given-names>RO</given-names></string-name>, <string-name><surname>Garcia-Carrasco</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Fuentes-Alexandro</surname>
<given-names>S</given-names></string-name>, et al. <article-title>Insulin resistance, chronic inflammatory state and the link with systemic lupus erythematosus-related coronary disease</article-title>. <source/><italic toggle="yes">Autoimmun Rev</italic>. <year>2006</year>;<volume>6</volume>(<issue>1</issue>):<fpage>48</fpage>–<lpage>53</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.autrev.2006.07.001</pub-id><pub-id pub-id-type="pmid">17110317</pub-id></mixed-citation>
</ref>
<ref id="CIT0006">
<label>6.</label>
<mixed-citation publication-type="journal"><string-name><surname>Ridker</surname>
<given-names>PM</given-names></string-name>, <string-name><surname>Luscher</surname>
<given-names>TF</given-names></string-name>. <article-title>Anti-inflammatory therapies for cardiovascular disease</article-title>. <source/><italic toggle="yes">Eur Heart J</italic>. <year>2014</year>;<volume>35</volume>(<issue>27</issue>):<fpage>1782</fpage>–<lpage>1791</lpage>. doi:<pub-id pub-id-type="doi">10.1093/eurheartj/ehu203</pub-id><pub-id pub-id-type="pmid">24864079</pub-id></mixed-citation>
</ref>
<ref id="CIT0007">
<label>7.</label>
<mixed-citation publication-type="journal"><string-name><surname>Schulte</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Sukhova</surname>
<given-names>GK</given-names></string-name>, <string-name><surname>Libby</surname>
<given-names>P</given-names></string-name>. <article-title>Genetically programmed biases in Th1 and Th2 immune responses modulate atherogenesis</article-title>. <source/><italic toggle="yes">Am J Pathol</italic>. <year>2008</year>;<volume>172</volume>(<issue>6</issue>):<fpage>1500</fpage>–<lpage>1508</lpage>. doi:<pub-id pub-id-type="doi">10.2353/ajpath.2008.070776</pub-id><pub-id pub-id-type="pmid">18467709</pub-id></mixed-citation>
</ref>
<ref id="CIT0008">
<label>8.</label>
<mixed-citation publication-type="journal"><string-name><surname>Petersen</surname>
<given-names>CM</given-names></string-name>, <string-name><surname>Nielsen</surname>
<given-names>MS</given-names></string-name>, <string-name><surname>Nykjaer</surname>
<given-names>A</given-names></string-name>, et al. <article-title>Molecular identification of a novel candidate sorting receptor purified from human brain by receptor-associated protein affinity chromatography</article-title>. <source/><italic toggle="yes">J Biol Chem</italic>. <year>1997</year>;<volume>272</volume>(<issue>6</issue>):<fpage>3599</fpage>–<lpage>3605</lpage>. doi:<pub-id pub-id-type="doi">10.1074/jbc.272.6.3599</pub-id><pub-id pub-id-type="pmid">9013611</pub-id></mixed-citation>
</ref>
<ref id="CIT0009">
<label>9.</label>
<mixed-citation publication-type="journal"><string-name><surname>Jacobsen</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Madsen</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Moestrup</surname>
<given-names>SK</given-names></string-name>, et al. <article-title>Molecular characterization of a novel human hybrid-type receptor that binds the alpha2-macroglobulin receptor-associated protein</article-title>. <source/><italic toggle="yes">J Biol Chem</italic>. <year>1996</year>;<volume>271</volume>(<issue>49</issue>):<fpage>31379</fpage>–<lpage>31383</lpage>. doi:<pub-id pub-id-type="doi">10.1074/jbc.271.49.31379</pub-id><pub-id pub-id-type="pmid">8940146</pub-id></mixed-citation>
</ref>
<ref id="CIT0010">
<label>10.</label>
<mixed-citation publication-type="journal"><string-name><surname>Patel</surname>
<given-names>KM</given-names></string-name>, <string-name><surname>Strong</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Tohyama</surname>
<given-names>J</given-names></string-name>, et al. <article-title>Macrophage sortilin promotes LDL uptake, foam cell formation, and atherosclerosis</article-title>. <source/><italic toggle="yes">Circ Res</italic>. <year>2015</year>;<volume>116</volume>(<issue>5</issue>):<fpage>789</fpage>–<lpage>796</lpage>. doi:<pub-id pub-id-type="doi">10.1161/CIRCRESAHA.116.305811</pub-id><pub-id pub-id-type="pmid">25593281</pub-id></mixed-citation>
</ref>
<ref id="CIT0011">
<label>11.</label>
<mixed-citation publication-type="journal"><string-name><surname>Rogaeva</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Meng</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Lee</surname>
<given-names>JH</given-names></string-name>, et al. <article-title>The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease</article-title>. <source/><italic toggle="yes">Nat Genet</italic>. <year>2007</year>;<volume>39</volume>(<issue>2</issue>):<fpage>168</fpage>–<lpage>177</lpage>. doi:<pub-id pub-id-type="doi">10.1038/ng1943</pub-id><pub-id pub-id-type="pmid">17220890</pub-id></mixed-citation>
</ref>
<ref id="CIT0012">
<label>12.</label>
<mixed-citation publication-type="journal"><string-name><surname>Mortensen</surname>
<given-names>MB</given-names></string-name>, <string-name><surname>Kjolby</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Gunnersen</surname>
<given-names>S</given-names></string-name>, et al. <article-title>Targeting sortilin in immune cells reduces proinflammatory cytokines and atherosclerosis</article-title>. <source/><italic toggle="yes">J Clin Invest</italic>. <year>2014</year>;<volume>124</volume>(<issue>12</issue>):<fpage>5317</fpage>–<lpage>5322</lpage>. doi:<pub-id pub-id-type="doi">10.1172/JCI76002</pub-id><pub-id pub-id-type="pmid">25401472</pub-id></mixed-citation>
</ref>
<ref id="CIT0013">
<label>13.</label>
<mixed-citation publication-type="journal"><string-name><surname>Yabe-Wada</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Matsuba</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Takeda</surname>
<given-names>K</given-names></string-name>, et al. <article-title>TLR signals posttranscriptionally regulate the cytokine trafficking mediator sortilin</article-title>. <source/><italic toggle="yes">Sci Rep</italic>. <year>2016</year>;<volume>6</volume>:<fpage>26566</fpage>. doi:<pub-id pub-id-type="doi">10.1038/srep26566</pub-id><pub-id pub-id-type="pmid">27220277</pub-id></mixed-citation>
</ref>
<ref id="CIT0014">
<label>14.</label>
<mixed-citation publication-type="journal"><string-name><surname>Larsen</surname>
<given-names>JV</given-names></string-name>, <string-name><surname>Petersen</surname>
<given-names>CM</given-names></string-name>. <article-title>SorLA in interleukin-6 signaling and turnover</article-title>. <source/><italic toggle="yes">Mol Cell Biol</italic>. <year>2017</year>;<volume>37</volume>(<issue>11</issue>):<fpage>e00641</fpage>. doi:<pub-id pub-id-type="doi">10.1128/MCB.00641-16</pub-id><pub-id pub-id-type="pmid">28265003</pub-id></mixed-citation>
</ref>
<ref id="CIT0015">
<label>15.</label>
<mixed-citation publication-type="journal"><string-name><surname>Sullivan</surname>
<given-names>SE</given-names></string-name>, <string-name><surname>Liao</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Smith</surname>
<given-names>RV</given-names></string-name>, et al. <article-title>Candidate-based screening via gene modulation in human neurons and astrocytes implicates FERMT2 in Abeta and TAU proteostasis</article-title>. <source/><italic toggle="yes">Hum Mol Genet</italic>. <year>2019</year>;<volume>28</volume>(<issue>5</issue>):<fpage>718</fpage>–<lpage>735</lpage>. doi:<pub-id pub-id-type="doi">10.1093/hmg/ddy376</pub-id><pub-id pub-id-type="pmid">30371777</pub-id></mixed-citation>
</ref>
<ref id="CIT0016">
<label>16.</label>
<mixed-citation publication-type="journal"><string-name><surname>Goettsch</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Iwata</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Hutcheson</surname>
<given-names>JD</given-names></string-name>, et al. <article-title>Serum sortilin associates with aortic calcification and cardiovascular risk in men</article-title>. <source/><italic toggle="yes">Arterioscler Thromb Vasc Biol</italic>. <year>2017</year>;<volume>37</volume>(<issue>5</issue>):<fpage>1005</fpage>–<lpage>1011</lpage>. doi:<pub-id pub-id-type="doi">10.1161/ATVBAHA.116.308932</pub-id><pub-id pub-id-type="pmid">28279970</pub-id></mixed-citation>
</ref>
<ref id="CIT0017">
<label>17.</label>
<mixed-citation publication-type="journal"><string-name><surname>T Cuenco</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Lunetta</surname>
<given-names>KL</given-names></string-name>, <string-name><surname>Baldwin</surname>
<given-names>CT</given-names></string-name>, et al. <article-title>Association of distinct variants in SORL1 with cerebrovascular and neurodegenerative changes related to Alzheimer disease</article-title>. <source/><italic toggle="yes">Arch Neurol</italic>. <year>2008</year>;<volume>65</volume>(<issue>12</issue>):<fpage>1640</fpage>–<lpage>1648</lpage>. doi:<pub-id pub-id-type="doi">10.1001/archneur.65.12.1640</pub-id><pub-id pub-id-type="pmid">19064752</pub-id></mixed-citation>
</ref>
<ref id="CIT0018">
<label>18.</label>
<mixed-citation publication-type="journal"><string-name><surname>Nielsen</surname>
<given-names>MS</given-names></string-name>, <string-name><surname>Jacobsen</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Olivecrona</surname>
<given-names>G</given-names></string-name>, et al. <article-title>Sortilin/neurotensin receptor-3 binds and mediates degradation of lipoprotein lipase</article-title>. <source/><italic toggle="yes">J Biol Chem</italic>. <year>1999</year>;<volume>274</volume>(<issue>13</issue>):<fpage>8832</fpage>–<lpage>8836</lpage>. doi:<pub-id pub-id-type="doi">10.1074/jbc.274.13.8832</pub-id><pub-id pub-id-type="pmid">10085125</pub-id></mixed-citation>
</ref>
<ref id="CIT0019">
<label>19.</label>
<mixed-citation publication-type="journal"><string-name><surname>Nilsson</surname>
<given-names>SK</given-names></string-name>, <string-name><surname>Christensen</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Raarup</surname>
<given-names>MK</given-names></string-name>, et al. <article-title>Endocytosis of apolipoprotein A-V by members of the low density lipoprotein receptor and the VPS10p domain receptor families</article-title>. <source/><italic toggle="yes">J Biol Chem</italic>. <year>2008</year>;<volume>283</volume>(<issue>38</issue>):<fpage>25920</fpage>–<lpage>25927</lpage>. doi:<pub-id pub-id-type="doi">10.1074/jbc.M802721200</pub-id><pub-id pub-id-type="pmid">18603531</pub-id></mixed-citation>
</ref>
<ref id="CIT0020">
<label>20.</label>
<mixed-citation publication-type="journal"><string-name><surname>Hu</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Padukkavidana</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Vaegter</surname>
<given-names>CB</given-names></string-name>, et al. <article-title>Sortilin-mediated endocytosis determines levels of the frontotemporal dementia protein, progranulin</article-title>. <source/><italic toggle="yes">Neuron</italic>. <year>2010</year>;<volume>68</volume>(<issue>4</issue>):<fpage>654</fpage>–<lpage>667</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.neuron.2010.09.034</pub-id><pub-id pub-id-type="pmid">21092856</pub-id></mixed-citation>
</ref>
<ref id="CIT0021">
<label>21.</label>
<mixed-citation publication-type="journal"><string-name><surname>Carlo</surname>
<given-names>AS</given-names></string-name>, <string-name><surname>Gustafsen</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Mastrobuoni</surname>
<given-names>G</given-names></string-name>, et al. <article-title>The pro-neurotrophin receptor sortilin is a major neuronal apolipoprotein E receptor for catabolism of amyloid-beta peptide in the brain</article-title>. <source/><italic toggle="yes">J Neurosci</italic>. <year>2013</year>;<volume>33</volume>(<issue>1</issue>):<fpage>358</fpage>–<lpage>370</lpage>. doi:<pub-id pub-id-type="doi">10.1523/JNEUROSCI.2425-12.2013</pub-id><pub-id pub-id-type="pmid">23283348</pub-id></mixed-citation>
</ref>
<ref id="CIT0022">
<label>22.</label>
<mixed-citation publication-type="journal"><string-name><surname>Goettsch</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Hutcheson</surname>
<given-names>JD</given-names></string-name>, <string-name><surname>Aikawa</surname>
<given-names>M</given-names></string-name>, et al. <article-title>Sortilin mediates vascular calcification via its recruitment into extracellular vesicles</article-title>. <source/><italic toggle="yes">J Clin Invest</italic>. <year>2016</year>;<volume>126</volume>(<issue>4</issue>):<fpage>1323</fpage>–<lpage>1336</lpage>. doi:<pub-id pub-id-type="doi">10.1172/JCI80851</pub-id><pub-id pub-id-type="pmid">26950419</pub-id></mixed-citation>
</ref>
<ref id="CIT0023">
<label>23.</label>
<mixed-citation publication-type="journal"><string-name><surname>Kjolby</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Andersen</surname>
<given-names>OM</given-names></string-name>, <string-name><surname>Breiderhoff</surname>
<given-names>T</given-names></string-name>, et al. <article-title>Sort1, encoded by the cardiovascular risk locus 1p13.3, is a regulator of hepatic lipoprotein export</article-title>. <source/><italic toggle="yes">Cell Metab</italic>. <year>2010</year>;<volume>12</volume>(<issue>3</issue>):<fpage>213</fpage>–<lpage>223</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.cmet.2010.08.006</pub-id><pub-id pub-id-type="pmid">20816088</pub-id></mixed-citation>
</ref>
<ref id="CIT0024">
<label>24.</label>
<mixed-citation publication-type="journal"><string-name><surname>Strong</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Ding</surname>
<given-names>Q</given-names></string-name>, <string-name><surname>AC</surname>
<given-names>E</given-names></string-name>, et al. <article-title>Hepatic sortilin regulates both apolipoprotein B secretion and LDL catabolism</article-title>. <source/><italic toggle="yes">J Clin Invest</italic>. <year>2012</year>;<volume>122</volume>(<issue>8</issue>):<fpage>2807</fpage>–<lpage>2816</lpage>. doi:<pub-id pub-id-type="doi">10.1172/JCI63563</pub-id><pub-id pub-id-type="pmid">22751103</pub-id></mixed-citation>
</ref>
<ref id="CIT0025">
<label>25.</label>
<mixed-citation publication-type="journal"><string-name><surname>Oh</surname>
<given-names>TJ</given-names></string-name>, <string-name><surname>Ahn</surname>
<given-names>CH</given-names></string-name>, <string-name><surname>Kim</surname>
<given-names>BR</given-names></string-name>, et al. <article-title>Circulating sortilin level as a potential biomarker for coronary atherosclerosis and diabetes mellitus</article-title>. <source/><italic toggle="yes">Cardiovasc Diabetol</italic>. <year>2017</year>;<volume>16</volume>(<issue>1</issue>):<fpage>92</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s12933-017-0568-9</pub-id><pub-id pub-id-type="pmid">28728579</pub-id></mixed-citation>
</ref>
<ref id="CIT0026">
<label>26.</label>
<mixed-citation publication-type="journal"><string-name><surname>Escarcega</surname>
<given-names>RO</given-names></string-name>, <string-name><surname>Lipinski</surname>
<given-names>MJ</given-names></string-name>, <string-name><surname>Garcia-Carrasco</surname>
<given-names>M</given-names></string-name>, et al. <article-title>Inflammation and atherosclerosis: cardiovascular evaluation in patients with autoimmune diseases</article-title>. <source/><italic toggle="yes">Autoimmun Rev</italic>. <year>2018</year>;<volume>17</volume>(<issue>7</issue>):<fpage>703</fpage>–<lpage>708</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.autrev.2018.01.021</pub-id><pub-id pub-id-type="pmid">29730525</pub-id></mixed-citation>
</ref>
<ref id="CIT0027">
<label>27.</label>
<mixed-citation publication-type="journal"><string-name><surname>Sarzi-Puttini</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Atzeni</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Shoenfeld</surname>
<given-names>Y</given-names></string-name>, et al. <article-title>TNF-alpha, rheumatoid arthritis, and heart failure: a rheumatological dilemma</article-title>. <source/><italic toggle="yes">Autoimmun Rev</italic>. <year>2005</year>;<volume>4</volume>(<issue>3</issue>):<fpage>153</fpage>–<lpage>161</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.autrev.2004.09.004</pub-id><pub-id pub-id-type="pmid">15823501</pub-id></mixed-citation>
</ref>
<ref id="CIT0028">
<label>28.</label>
<mixed-citation publication-type="journal"><string-name><surname>Ridker</surname>
<given-names>PM</given-names></string-name>. <article-title>From C-reactive protein to interleukin-6 to interleukin-1: moving upstream to identify novel targets for atheroprotection</article-title>. <source/><italic toggle="yes">Circ Res</italic>. <year>2016</year>;<volume>118</volume>(<issue>1</issue>):<fpage>145</fpage>–<lpage>156</lpage>. doi:<pub-id pub-id-type="doi">10.1161/CIRCRESAHA.115.306656</pub-id><pub-id pub-id-type="pmid">26837745</pub-id></mixed-citation>
</ref>
<ref id="CIT0029">
<label>29.</label>
<mixed-citation publication-type="journal"><string-name><surname>Kaptoge</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Seshasai</surname>
<given-names>SR</given-names></string-name>, <string-name><surname>Gao</surname>
<given-names>P</given-names></string-name>, et al. <article-title>Inflammatory cytokines and risk of coronary heart disease: new prospective study and updated meta-analysis</article-title>. <source/><italic toggle="yes">Eur Heart J</italic>. <year>2014</year>;<volume>35</volume>(<issue>9</issue>):<fpage>578</fpage>–<lpage>589</lpage>. doi:<pub-id pub-id-type="doi">10.1093/eurheartj/eht367</pub-id><pub-id pub-id-type="pmid">24026779</pub-id></mixed-citation>
</ref>
<ref id="CIT0030">
<label>30.</label>
<mixed-citation publication-type="journal"><string-name><surname>Patel</surname>
<given-names>AB</given-names></string-name>, <string-name><surname>Tsilioni</surname>
<given-names>I</given-names></string-name>, <string-name><surname>Leeman</surname>
<given-names>SE</given-names></string-name>, et al. <article-title>Neurotensin stimulates sortilin and mTOR in human microglia inhibitable by methoxyluteolin, a potential therapeutic target for autism</article-title>. <source/><italic toggle="yes">Proc Natl Acad Sci U S A</italic>. <year>2016</year>;<volume>113</volume>(<issue>45</issue>):<fpage>E7049</fpage>- <lpage>E7058</lpage>. doi:<pub-id pub-id-type="doi">10.1073/pnas.1604992113</pub-id><pub-id pub-id-type="pmid">27663735</pub-id></mixed-citation>
</ref>
<ref id="CIT0031">
<label>31.</label>
<mixed-citation publication-type="journal"><string-name><surname>Samani</surname>
<given-names>NJ</given-names></string-name>, <string-name><surname>Erdmann</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Hall</surname>
<given-names>AS</given-names></string-name>, et al. <article-title>Genomewide association analysis of coronary artery disease</article-title>. <source/><italic toggle="yes">N Engl J Med</italic>. <year>2007</year>;<volume>357</volume>(<issue>5</issue>):<fpage>443</fpage>–<lpage>453</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJMoa072366</pub-id><pub-id pub-id-type="pmid">17634449</pub-id></mixed-citation>
</ref>
<ref id="CIT0032">
<label>32.</label>
<mixed-citation publication-type="journal"><string-name><surname>Schunkert</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Konig</surname>
<given-names>IR</given-names></string-name>, <string-name><surname>Kathiresan</surname>
<given-names>S</given-names></string-name>, et al. <article-title>Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease</article-title>. <source/><italic toggle="yes">Nat Genet</italic>. <year>2011</year>;<volume>43</volume>(<issue>4</issue>):<fpage>333</fpage>–<lpage>338</lpage>. doi:<pub-id pub-id-type="doi">10.1038/ng.784</pub-id><pub-id pub-id-type="pmid">21378990</pub-id></mixed-citation>
</ref>
<ref id="CIT0033">
<label>33.</label>
<mixed-citation publication-type="journal"><string-name><surname>Musunuru</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Strong</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Frank-Kamenetsky</surname>
<given-names>M</given-names></string-name>, et al. <article-title>From noncoding variant to phenotype via SORT1 at the 1p13 cholesterol locus</article-title>. <source/><italic toggle="yes">Nature</italic>. <year>2010</year>;<volume>466</volume>(<issue>7307</issue>):<fpage>714</fpage>–<lpage>719</lpage>. doi:<pub-id pub-id-type="doi">10.1038/nature09266</pub-id><pub-id pub-id-type="pmid">20686566</pub-id></mixed-citation>
</ref>
<ref id="CIT0034">
<label>34.</label>
<mixed-citation publication-type="journal"><string-name><surname>Kleber</surname>
<given-names>ME</given-names></string-name>, <string-name><surname>Renner</surname>
<given-names>W</given-names></string-name>, <string-name><surname>Grammer</surname>
<given-names>TB</given-names></string-name>, et al. <article-title>Association of the single nucleotide polymorphism rs599839 in the vicinity of the sortilin 1 gene with LDL and triglyceride metabolism, coronary heart disease and myocardial infarction. The Ludwigshafen risk and cardiovascular health study</article-title>. <source/><italic toggle="yes">Atherosclerosis.</italic>
<year>2010</year>;<volume>209</volume>(<issue>2</issue>):<fpage>492</fpage>–<lpage>497</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2009.09.068</pub-id><pub-id pub-id-type="pmid">19837406</pub-id></mixed-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>